Recurrence-free survival in breast cancer improved by adjuvant tamoxifen -especially for progesterone receptor positive tumors with a high proliferation

[1]  L. Skoog,et al.  The Stockholm trial on adjuvant tamoxifen in early breast cancer , 1987, Breast Cancer Research and Treatment.

[2]  D. Hedley,et al.  Consensus review of the clinical utility of DNA cytometry in carcinoma of the breast , 1993, Breast Cancer Research and Treatment.

[3]  M. Fernö,et al.  ERBB2 amplification is associated with tamoxifen resistance in steroid-receptor positive breast cancer. , 1994, Cancer letters.

[4]  A. Howell,et al.  Effect of tamoxifen on Ki67 labelling index in human breast tumours and its relationship to oestrogen and progesterone receptor status. , 1993, British Journal of Cancer.

[5]  W. McGuire,et al.  Prognostic significance of progesterone receptor levels in estrogen receptor-positive patients with metastatic breast cancer treated with tamoxifen: results of a prospective Southwest Oncology Group study. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  J. Prud'homme,et al.  Enzyme‐linked immunosorbent assay of ps2 in breast cancers, benign tumors, and normal breast tissues correlation with prognosis and adjuvant hormone therapy , 1992, Cancer.

[7]  R. Camplejohn,et al.  DNA flow cytometry and response to preoperative chemotherapy for primary breast cancer. , 1992, European journal of cancer.

[8]  Anthony Howell,et al.  Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Early Breast Cancer Trialists' Collaborative Group. , 1992 .

[9]  A. D. Schryver,et al.  Systemic treatment of early breast-cancer by hormonal, cytotoxic, or immune therapy: 133 randomized trials involving 31000 recurrences and 24000 deaths among 75000 women: 1 , 1992 .

[10]  I. Ellis,et al.  Hormone sensitivity in breast cancer: influence of heterogeneity of oestrogen receptor expression and cell proliferation. , 1991, European journal of cancer.

[11]  Douglas G. Altman,et al.  Practical statistics for medical research , 1990 .

[12]  V. Jordan,et al.  Endocrine pharmacology of antiestrogens as antitumor agents. , 1990, Endocrine reviews.

[13]  M. Fernö,et al.  Flow cytometry in primary breast cancer: improving the prognostic value of the fraction of cells in the S-phase by optimal categorisation of cut-off levels. , 1990, British Journal of Cancer.

[14]  M. Fernö,et al.  Indicators of prognosis in node-negative breast cancer. , 1990, The New England journal of medicine.

[15]  M. Fernö,et al.  Estrogen and Progesterone Receptor Analyses in More Than 4000 Human Breast Cancer Samples: A Study with Special Reference to Age at diagnosis and stability of analyses , 1990 .

[16]  U. Holst,et al.  Statistical evaluation of cell kinetic data from DNA flow cytometry (FCM) by the EM algorithm. , 1989, Cytometry.

[17]  H. Magdelenat,et al.  Correlation of pretreatment proliferative activity of breast cancer with the response to cytotoxic chemotherapy. , 1989, Journal of the National Cancer Institute.

[18]  G M Clark,et al.  Prediction of relapse or survival in patients with node-negative breast cancer by DNA flow cytometry. , 1989, The New England journal of medicine.

[19]  M. Fernö,et al.  Enzyme immunoassay of progesterone receptor in breast cancer biopsy samples. A comparison with the dextran coated charcoal method. , 1989, Acta oncologica.

[20]  M. Devonec,et al.  Flow cytometry analysis of the growth inhibitory effect of 4-hydroxy-tamoxifen on a human breast carcinoma cell line. , 1988, Anticancer research.

[21]  M. Fernö,et al.  Prognostic significance of estrogen and progesterone receptors in stage ii breast cancer , 1988, Journal of surgical oncology.

[22]  ADJUVANT TAMOXIFEN IN THE MANAGEMENT OF OPERABLE BREAST CANCER: THE SCOTTISH TRIAL Report from the Breast Cancer Trials Committee, Scottish Cancer Trials Office (MRC), Edinburgh , 1987, The Lancet.

[23]  O. Kallioniemi,et al.  Aneuploid DNA content and high S-phase fraction of tumour cells are related to poor prognosis in patients with primary breast cancer. , 1987, European journal of cancer & clinical oncology.

[24]  R. Derynck,et al.  Evidence that transforming growth factor-β is a hormonally regulated negative growth factor in human breast cancer cells , 1987, Cell.

[25]  R. Sutherland,et al.  Mechanisms of growth inhibition by nonsteroidal antioestrogens in human breast cancer cells. , 1987, Journal of steroid biochemistry.

[26]  M. Fernö,et al.  Enzyme immuno assay of the estrogen receptor in breast cancer biopsy samples. A comparison with isoelectric focusing. , 1986, Acta radiologica. Oncology.

[27]  CONTROLLED TRIAL OF TAMOXIFEN AS SINGLE ADJUVANT AGENT IN MANAGEMENT OF EARLY BREAST CANCER Analysis at Six Years by Nolvadex Adjuvant Trial Organisation , 1985, The Lancet.

[28]  B. Rasmussen,et al.  BENEFICIAL EFFECT OF ADJUVANT TAMOXIFEN THERAPY IN PRIMARY BREAST CANCER PATIENTS WITH HIGH OESTROGEN RECEPTOR VALUES , 1985, The Lancet.

[29]  Robert C. Leif,et al.  Convention on nomenclature for DNA cytometry , 1984 .

[30]  E. Rasch,et al.  Picogram per cell determination of DNA by flow cytofluorometry. , 1984, Analytical biochemistry.

[31]  M. Fernö,et al.  A comparison of two steroid receptor assays in breast cancer: dextran coated charcoal and isoelectric focusing. , 1983, Anticancer research.

[32]  I J Christensen,et al.  Standardization of high-resolution flow cytometric DNA analysis by the simultaneous use of chicken and trout red blood cells as internal reference standards. , 1983, Cytometry.

[33]  E. Sugarbaker,et al.  Preparation of tissues for DNA flow cytometric analysis. , 1980, Cytometry.

[34]  David A. Schoenfeld,et al.  Chi-squared goodness-of-fit tests for the proportional hazards regression model , 1980 .

[35]  B. Nordenskjöld,et al.  3H-thymidine incorporation into mammary carcinoma cells obtained by needle aspiration before and during endocrine therapy. , 1976, Acta cytologica.

[36]  W. Göhde,et al.  Analysis of PCP-data to determine the fraction of cells in the various phases of cell cycle , 1975, Radiation and environmental biophysics.

[37]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[38]  I. Richard Savage,et al.  CONTRIBUTIONS TO THE THEORY OF RANK ORDER STATISTICS THE TWO SAMPLE CASE: FINE STRUCTURE OF THE ORDERING OF PROBABILITIES OF RANK ORDERS , 1956 .

[39]  O. N. Meland,et al.  Carcinoma of the breast. , 1948, Annals of western medicine and surgery.

[40]  D.,et al.  Regression Models and Life-Tables , 2022 .